Maryland biotech Sensei Biotherapeutics Inc. has officially moved to the public arena. The Rockville immunotherapy company, which develops cancer therapeutics, made its debut on the Nasdaq Global Market Feb. 4 poised to secure $133 million in proceeds from the offering. That’s after increasing its inaugural share price to $19 for more than 7 million shares of common stock. The IPO was scheduled to close Monday, subject to satisfying customary closing conditions.
Rockville immunotherapy company Sensei Biotherapeutics executes $133M IPO
February 9, 2021
